Literature DB >> 31641008

A TAZ-ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer.

Wen-Hsuan Yang1,2,3, Zhiqing Huang4,5, Jianli Wu1,2, Chien-Kuang C Ding1,2, Susan K Murphy4,5, Jen-Tsan Chi6,2.   

Abstract

Ovarian cancer is the deadliest gynecologic cancer. Despite recent advances, clinical outcomes remain poor, necessitating novel therapeutic approaches. To investigate metabolic susceptibility, we performed nutrigenetic screens on a panel of clear cell and serous ovarian cancer cells and identified cystine addiction and vulnerability to ferroptosis, a novel form of regulated cell death. Our results may have therapeutic potential, but little is known about the determinants of ferroptosis susceptibility in ovarian cancer. We found that vulnerability to ferroptosis in ovarian cancer cells is enhanced by lower cell confluency. Because the Hippo pathway effectors Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) are recognized as sensors of cell density, and TAZ is the predominant effector in the tested ovarian cancer cell lines, we investigated the role of TAZ in ferroptosis of ovarian cancer. TAZ removal confers ferroptosis resistance, while TAZS89A overexpression sensitizes cells to ferroptosis. In addition, we found that lower TAZ level in chemo-resistant recurrent ovarian cancer is responsible for reduced ferroptosis susceptibility. The integrative genomic analysis identified ANGPTL4 as a direct TAZ-regulated target gene that sensitizes ferroptosis by activating NOX2. Collectively, cell density-regulated ferroptosis in ovarian cancer is mediated by TAZ through the regulation of the ANGPTL4-NOX2 axis, suggesting therapeutic potentials for ovarian cancers and other TAZ-activated tumors. IMPLICATIONS: This study reveals that TAZ promotes ferroptosis in ovarian cancers by regulating ANGPTL4 and NOX, offering a novel therapeutic potential for ovarian tumors with TAZ activation. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31641008      PMCID: PMC6942206          DOI: 10.1158/1541-7786.MCR-19-0691

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  44 in total

1.  TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway.

Authors:  Qun-Ying Lei; Heng Zhang; Bin Zhao; Zheng-Yu Zha; Feng Bai; Xin-Hai Pei; Shimin Zhao; Yue Xiong; Kun-Liang Guan
Journal:  Mol Cell Biol       Date:  2008-01-28       Impact factor: 4.272

2.  Regulation of ferroptotic cancer cell death by GPX4.

Authors:  Wan Seok Yang; Rohitha SriRamaratnam; Matthew E Welsch; Kenichi Shimada; Rachid Skouta; Vasanthi S Viswanathan; Jaime H Cheah; Paul A Clemons; Alykhan F Shamji; Clary B Clish; Lewis M Brown; Albert W Girotti; Virginia W Cornish; Stuart L Schreiber; Brent R Stockwell
Journal:  Cell       Date:  2014-01-16       Impact factor: 41.582

3.  TEAD mediates YAP-dependent gene induction and growth control.

Authors:  Bin Zhao; Xin Ye; Jindan Yu; Li Li; Weiquan Li; Siming Li; Jianjun Yu; Jiandie D Lin; Cun-Yu Wang; Arul M Chinnaiyan; Zhi-Chun Lai; Kun-Liang Guan
Journal:  Genes Dev       Date:  2008-06-25       Impact factor: 11.361

Review 4.  Anoikis resistance and tumor metastasis.

Authors:  Craig D Simpson; Kika Anyiwe; Aaron D Schimmer
Journal:  Cancer Lett       Date:  2008-06-24       Impact factor: 8.679

Review 5.  Current management strategies for ovarian cancer.

Authors:  Giovanni D Aletti; Mary M Gallenberg; William A Cliby; Aminah Jatoi; Lynn C Hartmann
Journal:  Mayo Clin Proc       Date:  2007-06       Impact factor: 7.616

6.  Genome-wide mapping of in vivo protein-DNA interactions.

Authors:  David S Johnson; Ali Mortazavi; Richard M Myers; Barbara Wold
Journal:  Science       Date:  2007-05-31       Impact factor: 47.728

7.  YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers.

Authors:  Claudia Stein; Anaïs Flore Bardet; Guglielmo Roma; Sebastian Bergling; Ieuan Clay; Alexandra Ruchti; Claudia Agarinis; Tobias Schmelzle; Tewis Bouwmeester; Dirk Schübeler; Andreas Bauer
Journal:  PLoS Genet       Date:  2015-08-21       Impact factor: 5.917

8.  Comprehensive profiling of amino acid response uncovers unique methionine-deprived response dependent on intact creatine biosynthesis.

Authors:  Xiaohu Tang; Melissa M Keenan; Jianli Wu; Chih-An Lin; Laura Dubois; J Will Thompson; Stephen J Freedland; Susan K Murphy; Jen-Tsan Chi
Journal:  PLoS Genet       Date:  2015-04-07       Impact factor: 5.917

9.  Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth.

Authors:  Shira L Cramer; Achinto Saha; Jinyun Liu; Surendar Tadi; Stefano Tiziani; Wupeng Yan; Kendra Triplett; Candice Lamb; Susan E Alters; Scott Rowlinson; Yan Jessie Zhang; Michael J Keating; Peng Huang; John DiGiovanni; George Georgiou; Everett Stone
Journal:  Nat Med       Date:  2016-11-21       Impact factor: 53.440

10.  Epidermal growth factor-induced ANGPTL4 enhances anoikis resistance and tumour metastasis in head and neck squamous cell carcinoma.

Authors:  Y-H Liao; K-H Chiang; J-M Shieh; C-R Huang; C-J Shen; W-C Huang; B-K Chen
Journal:  Oncogene       Date:  2016-10-31       Impact factor: 9.867

View more
  60 in total

Review 1.  Transcription factors in ferroptotic cell death.

Authors:  Chongshan Dai; Xin Chen; Jingbo Li; Paul Comish; Rui Kang; Daolin Tang
Journal:  Cancer Gene Ther       Date:  2020-03-03       Impact factor: 5.987

2.  DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway.

Authors:  Chao-Chieh Lin; Wen-Hsuan Yang; Yi-Tzu Lin; Xiaohu Tang; Po-Han Chen; Chien-Kuang Cornelia Ding; Dan Chen Qu; James V Alvarez; Jen-Tsan Chi
Journal:  Oncogene       Date:  2021-02-18       Impact factor: 9.867

Review 3.  Tumour fatty acid metabolism in the context of therapy resistance and obesity.

Authors:  Andrew J Hoy; Shilpa R Nagarajan; Lisa M Butler
Journal:  Nat Rev Cancer       Date:  2021-08-20       Impact factor: 60.716

Review 4.  Organelle-specific regulation of ferroptosis.

Authors:  Xin Chen; Rui Kang; Guido Kroemer; Daolin Tang
Journal:  Cell Death Differ       Date:  2021-08-31       Impact factor: 12.067

Review 5.  Cellular degradation systems in ferroptosis.

Authors:  Xin Chen; Chunhua Yu; Rui Kang; Guido Kroemer; Daolin Tang
Journal:  Cell Death Differ       Date:  2021-01-18       Impact factor: 15.828

6.  The Hippo Pathway Effector YAP Promotes Ferroptosis via the E3 Ligase SKP2.

Authors:  Wen-Hsuan Yang; Chao-Chieh Lin; Jianli Wu; Pei-Ya Chao; Kuan Chen; Po-Han Chen; Jen-Tsan Chi
Journal:  Mol Cancer Res       Date:  2021-03-11       Impact factor: 5.852

Review 7.  Context-dependent roles of YAP/TAZ in stem cell fates and cancer.

Authors:  Lucy LeBlanc; Nereida Ramirez; Jonghwan Kim
Journal:  Cell Mol Life Sci       Date:  2021-02-13       Impact factor: 9.261

Review 8.  Ferroptosis: machinery and regulation.

Authors:  Xin Chen; Jingbo Li; Rui Kang; Daniel J Klionsky; Daolin Tang
Journal:  Autophagy       Date:  2020-08-26       Impact factor: 16.016

9.  The Activation of Endothelial Cells Relies on a Ferroptosis-Like Mechanism: Novel Perspectives in Management of Angiogenesis and Cancer Therapy.

Authors:  Filipa Lopes-Coelho; Filipa Martins; Ana Hipólito; Cindy Mendes; Catarina O Sequeira; Rita F Pires; António M Almeida; Vasco D B Bonifácio; Sofia A Pereira; Jacinta Serpa
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

10.  Identification and validation of a novel glycolysis-related gene signature for predicting the prognosis in ovarian cancer.

Authors:  Jing Yu; Ting-Ting Liu; Lei-Lei Liang; Jing Liu; Hong-Qing Cai; Jia Zeng; Tian-Tian Wang; Jian Li; Lin Xiu; Ning Li; Ling-Ying Wu
Journal:  Cancer Cell Int       Date:  2021-07-06       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.